Ding X, et al. - The benefits of antiplatelet (AP) resumption on preventing ischemic or thromboembolic events against its risks of promoting intracranial hemorrhage (ICH) recurrence or hematoma expansion were evaluated in this meta-analysis. In patients with primary ICH, AP resumption reduced the risk of ischemic or thromboembolic events, without significant increase of risk of ICH recurrence or hematoma expansion.